US Patent Issued to Genzyme on Nov. 25 for "Compositions and methods for treating and preventing macular degeneration" (Massachusetts Inventor)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,483,047, issued on Nov. 25, was assigned to Genzyme Corp. (Cambridge, Mass.).

"Compositions and methods for treating and preventing macular degeneration" was invented by Abraham Scaria (Framingham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods for treating macular degeneration are disclosed. The methods utilize gene delivery to human eyes of soluble Flt-1 receptors, as well fusion proteins including a soluble Flt-1 receptor."

The patent was filed on Feb. 25, 2022, under Application No. 17/681,468.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1...